Margaret A. Alexander bought $4,971 of OVID
President and COO at Ovid Therapeutics Inc.. 6,810 shares at an average of $0.73, traded Jan 27, 2025, filed Jan 29, 2025.
Score components
- +20RolePresident
- 0Trade size$5k at market
- +6Relative to holdingsHoldings up 24%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -28.5%, 3m -55.9%, 6m -32.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-002230, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 27, 2025 | POpen-market purchase Common Stock | +6,810 | $0.73 | $4,971 | 34,935 | Jan 29, 2025 |
Related signals
Other insiders at Ovid Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Ovid Therapeutics Inc. | Margaret A. Alexander President and CEO | $17k 11,656 shares | -16% | |
| 23Weak | Ovid Therapeutics Inc. | Jeffrey A Rona CBFO | $12k 8,541 shares | -9% | |
| 20Weak | OVIDsell Ovid Therapeutics Inc. | Margaret A. Alexander President and COO | $2,956 5,279 shares | -7% | |
| 35Weak | OVIDbuy Ovid Therapeutics Inc. | Jeremy M Levin CEO | $50k 18,248 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.